Last updated: February 15, 2026
What is the drug associated with NDC 50474-0596?
The National Drug Code (NDC) 50474-0596 corresponds to Ruxolitinib, marketed under the brand name Jakafi. It is a Janus kinase (JAK) inhibitor approved by the FDA for myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD).
Market Size and Revenue Trends
- Current Market Valuation: The global JAK inhibitor market was valued at approximately $10 billion in 2022.
- Estimated Market Share (Jakafi): Estimated to account for roughly 60% of the JAK inhibitor market, given its FDA approvals and market penetration.
- Growth Rate: The market is projected to grow at a compound annual growth rate (CAGR) of 7% from 2023 to 2030.
- Key Competitors: Other drugs targeting similar indications include Fedratinib (Inrebic) and Itacitinib (in development). Terapeutic competition may influence market share over time.
Indication-Specific Market Dynamics
-
Myelofibrosis: Estimated at a 2023 prevalence of around 35,000 patients in the U.S. alone. Ruxolitinib’s market penetration is high with >80% of diagnosed patients receiving treatment.
-
Polycythemia Vera (PV): Approximate 2023 prevalence in the U.S. of 54,000 patients. Ruxolitinib, as a second-line therapy, accounts for roughly 40% of PV prescriptions.
-
Graft-versus-host disease (GVHD): An emerging indication with limited data but growing adoption, expected to expand the market segment.
Pricing and Revenue Projections
Current Pricing (U.S. Market):
- Average Wholesale Price (AWP): Approx. $1,850 per 20 mg tablet.
- Average Monthly Cost: Roughly $15,000 for a typical treatment course.
- Total Annual Cost: Estimated at $180,000 per patient.
Projected Price Trajectory (2023-2030):
| Year |
Estimated Wholesale Price (per 20 mg tablet) |
Notes |
| 2023 |
$1,850 |
Current pricing |
| 2025 |
$1,850 - $2,000 |
Inflation and market pressures |
| 2030 |
$2,000 - $2,200 |
Possible price increases due to demand or manufacturing costs |
Note: These are wholesale prices; net prices to payers are typically 20-25% lower.
Factors Influencing Price Trends
- Patent Life: Jakafi's patent extends until 2027-2029 in key markets, delaying generics entry.
- Generic Competition: Entry of biosimilars or generic versions could lower prices by 30-50%, beginning around 2028-2030.
- Market Penetration: Increasing adoption in non-approved indications (e.g., autoimmune diseases) may exert downward pressure.
- Pricing Regulations: In some countries, governmental price controls could limit increases.
Regulatory and Patent Considerations
- Patent Expiry: Protected until late 2027; legal barriers delay generic entry.
- Orphan Drug Status: For some indications, extends exclusivity rights and pricing power.
Future Revenue Projections (U.S. Market)
| Year |
Estimated Patients |
Estimated Revenue (USD billions) |
Assumptions |
| 2023 |
20,000 |
3.6 |
Current prevalence and market share |
| 2025 |
22,000 |
4.0 |
Slight increase in indications and patient access |
| 2030 |
25,000 |
5.0 |
Expanded indications and stable prices |
Note: Assumes stable market share and no significant generic competition until late 2020s.
Summary
- NDC 50474-0596 (Ruxolitinib/Jakafi) faces a growing market driven by steady prevalence of key indications.
- Price per unit is relatively high but expected to increase modestly until patent expiration, after which significant price reductions could occur.
- Market expansion into new indications and geographic regions may sustain revenue growth.
- Competition and regulation are primary risks to sustained pricing power.
Key Takeaways
- The drug remains a market leader in JAK inhibitors with high current pricing and entrenched patent protection.
- Market growth depends on expanding indications and geographic reach.
- Price erosion anticipated post-2027 due to biosimilar and generic entry.
- The overall market is expected to reach approximately $15 billion globally by 2030, with Jakafi maintaining a dominant share until patent expiry.
- Developers and investors should monitor patent statuses, regulatory changes, and competitive product pipelines closely.
FAQs
1. When will generic versions of Ruxolitinib likely enter the market?
Around 2027-2029, following patent expiration and biosimilar approval pathways.
2. How might regulatory changes impact pricing?
Price controls or negotiation policies in certain markets could cap prices, especially in Europe and Asia.
3. What are the main drivers of growth in the Ruxolitinib market?
Increasing prevalence of approved indications, expanding to new markets, and potential new indications.
4. How does competition from other JAK inhibitors affect Ruxolitinib?
New entrants or patent challenges could reduce market share and pricing power.
5. What is the outlook for Ruxolitinib’s revenue beyond 2030?
Revenue decline expected post-patent due to generics, unless new indications or formulations sustain demand.
References
[1] MarketResearch.com, "Global JAK Inhibitors Market," 2022.
[2] FDA Drug Database, "Ruxolitinib (Jakafi)," 2023.
[3] IQVIA Data, "Prescription Trends for Myelofibrosis and PV," 2023.
[4] EvaluatePharma, "Oncology Market Forecast," 2023.
[5] U.S. Patent and Trademark Office, "Jakafi Patent Status," 2023.
